Just got back from a conference in Korea. Everyone there is talking about mitochondrial biology and looking for drugs or methods to improve or replace mitochondria?
Anyone looked into this space before? What are some of the leading companies?
Just got back from a conference in Korea. Everyone there is talking about mitochondrial biology and looking for drugs or methods to improve or replace mitochondria?
Anyone looked into this space before? What are some of the leading companies?
Just posted our summary notes for the quarter for $ISRG, you can read it here: https://t.co/35KzQhyuYT
Just need to be a free member to read, there is no need to be a paid subscriber.
@RussFaigen@earnings_guy Just posted our summary notes for the quarter, you can read it here: https://t.co/35KzQhyuYT
Just need to be a free member to read, there is no need to be a paid subscriber.
@AlphaSenseInc Just posted our summary notes for the quarter, you can read it here: https://t.co/35KzQhyuYT
Just need to be a free member to read, there is no need to be a paid subscriber.
@wallstengine Just posted our summary notes for the quarter, you can read it here: https://t.co/35KzQhyuYT
Just need to be a free member to read, there is no need to be a paid subscriber.
@Brian_Stoffel_ Just posted our summary notes for the quarter, you can read it here: https://t.co/35KzQhyuYT
Just need to be a free member to read, there is no need to be a paid subscriber.
My Top 10 Ideas:
These are companies I think have great fundamentals. Please do you own DD.
1. $INSM
2. $BBIO
3. $PTGX
4. $PRAX
5. $MIRM
6. $COGT
7. $MDGL
8. $IDYA
9. $IMNM
10. $DFTX
Generics vs Biosimilars - Where is the difference
For a generic, the chemistry is the product.
For a biosimilar, the process is the product.
This high barrier is the root of most of the commercial and margin differences.
$SDZ $TEVA
https://t.co/B5tLlzFatX
$SYK enters soft tissue robotics through partnership with CMR surgical.
Exciting time ahead. You can read our deep dives on $ISRG and $SYK on our site. Link in profile.
Citeline candidates for Biotech of the year:
Abivax - $ABVX - Potentially best-in-disease phase 3 data for obefazimod in ulcerative colitis.
Celcuity - $CELC - Phase 3 win for gedatolisib (comprehensive PI3K/AKT/mTOR pathway inhibition) in HR+/HER2− breast cancer.
Ichnos Glenmark Innovation - Private - First-in-class BCMA × CD38 × CD3 trispecific for multiple myeloma (licensed to AbbVie).
Insmed - $INSM - The first approved treatment for bronchiectasis (brensocatib).
Kailera Therapeutics - $KLRA - Strong phase 2 obesity data with their dual GLP1/GIP receptor agonist, Ribupatide.
Mirum Pharmaceuticals - $MIRM - Could become the first treatment for cholestatic pruritus in primary sclerosing cholangitis (PSC).
Parabilis Medicines - $PBLS - Zolucatetide, the first direct β-catenin:TCF inhibitor, with promise in desmoid tumours.
Revolution Medicines - $RVMD - Daraxonrasib, the first pan-RAS inhibitor, approved for pancreatic cancer.
@OptionWell Thanks for sharing Jeff. Been following you for a while now.
Just wanted to check what do you mean by they don’t pay well? I thought the target was 1% a month. Thanks.
The first biosimilar breaks the ice, but the second triggers the price drop📉
Data shows a 2nd biosimilar launched within 3 years nearly doubles ASP pressure (dropping from -23% to -40% by Year 3).
While 3+ entrants drive prices down to -48%, marginal returns decline after #2.
I believe the above picture is a good overview of what happens. Prices drop about 48% after more than 2 biosimilars come to market. I don’t believe it makes sense for anyone else to enter the market after that. Takes about 6-7 years to make a biosim, cost 100-300m